GlassScriptPhysician profile
Kimberly A Behnk
NPI 1003484965
$2,545.63
in general payments reported to CMS, 2019-2025
18 companies · $20.60 in 2025
The $20.60 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.99 · 2022: $314 · 2023: $1,894 · 2024: $268 · 2025: $20.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210 · Travel and Lodging: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.69 |
| Travel and Lodging | $973.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,404.60 | 2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $506.86 | 2022-2023 | |
| Novo Nordisk INC | $116.55 | 2024 | |
| Argenx US, INC. | $87.25 | 2022-2023 | Vyvgart |
| Csl Behring | $48.95 | 2022 | |
| Acadia Pharmaceuticals INC | $43.32 | 2022-2023 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $39.61 | 2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $37.63 | 2023-2024 | |
| Biogen, INC. | $36.19 | 2021 | |
| Travere Therapeutics, INC. | $35.38 | 2024 | |
| Fresenius USA Marketing, INC. | $34.99 | 2024 | |
| Calliditas Therapeutics US INC. | $33.56 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $26.52 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.31 | 2022 | |
| Celgene Corporation | $19.89 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $18.07 | 2024 | Ibsrela |
| Lundbeck LLC | $17.91 | 2022 | |
| Allergan, INC. | $16.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Behnk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.